Ownership history in Dempze Nancy E · 8 quarters on record
This page tracks every 13F SEC filing in which Dempze Nancy E reported a position in VERTEX PHARMACEUTICALS (VRTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | REDUCED | 7,058 | -194 | -2.7% | 1.67% | $3.2M | $453.36 |
| 2025 Q3 | ADDED | 7,252 | +72 | +1.0% | 1.56% | $2.8M | $391.64 |
| 2025 Q2 | ADDED | 7,180 | +117 | +1.7% | 1.84% | $3.2M | $445.20 |
| 2025 Q1 | ADDED | 7,063 | +986 | +16.2% | 2.06% | $3.4M | $484.82 |
| 2024 Q4 | ADDED | 6,077 | +1,208 | +24.8% | 1.41% | $2.4M | $402.70 |
| 2024 Q3 | ADDED | 4,869 | +2,286 | +88.5% | 1.26% | $2.3M | $465.08 |
| 2024 Q2 | ADDED | 2,583 | +1,878 | +266.4% | 0.83% | $1.2M | $468.72 |
| 2024 Q1 | INITIATED | 705 | — | — | 0.22% | $295K | — |
As of 2025 Q4 — sorted by position size